MIT Koch Institute to Roche LightCycler(R) 480 system use to advance cancer research

Current article ratings:
Patients / public:healthcare Prof:
Roche (six: RO, ROG;) OTCQX: RHHBY) today announced that the David H. Koch Institute for integrative cancer research at MIT Roche LightCycler ® 480 system, a real time Polymerase chain reaction (PCR) system to be used for the analysis of gene expression and genetic variation in advanced cancer research.

The Koch Institute plans, use the LightCycler ® 480 system, support to several key areas of research it has determined is critical for rapid progress in the control of cancer, and engineering as such as the molecular and cellular basis of metastasis explore-the immune system to fight cancer. The Institute with the Massachusetts Institute of technology in Cambridge, Massachusetts is "our approach at MIT offers a unique collaboration between scientists and engineers, which has helped us place at the forefront of the fight against cancer," said Robert urban, executive Director of the Koch Institute. "The LightCycler ® offer the platform devices to help us to use the many applications for real-time PCR technology in cancer research."

The LightCycler ® 480 system is a fully integrated, 96-well and 384-well plate based real-time PCR platform for the qualitative and quantitative detection of nucleic acids. He can in a variety of applications in research, how gene expression be used studies, identification and analysis of genetic variation or array data validation.

Source:
Roche